Syngen Biotech Co., Ltd.

As of June 30, 2026, Syngen Biotech Co., Ltd. carries a market capitalization of 2.41B, placing it among publicly traded companies globally. Its enterprise value stands at 2.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Syngen Biotech Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Syngen Biotech Co., Ltd. has 27.10M shares outstanding.

As of June 30, 2026, Syngen Biotech Co., Ltd. trades at a trailing price-to-earnings ratio of 10.54. The price-to-sales ratio is 1.15, and the price-to-book ratio stands at 1.03.

As of June 30, 2026, Syngen Biotech Co., Ltd. trades at an EV/EBITDA multiple of 6.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.83 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Syngen Biotech Co., Ltd. trades at an EV/FCF ratio of 86.51, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.48B versus a market cap of 2.41B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Syngen Biotech Co., Ltd. maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.69, indicating elevated leverage, while an interest coverage ratio of 89.11 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Syngen Biotech Co., Ltd. posted a return on equity (ROE) of 10.15, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.83, useful for judging operating efficiency across full business cycles. The company generates approximately 7.18M in revenue per employee across its workforce of 292.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.62 indicates how many times Syngen Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Syngen Biotech Co., Ltd. recorded 54.15M in income tax expense. That works out to an effective tax rate of 19.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 282.71M, leaving 228.56M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Syngen Biotech Co., Ltd.'s stock has declined approximately 40.15% over the past 52 weeks. The 50-day moving average sits at 81.17, while the 200-day moving average is 99.61.

Over the twelve months ended June 30, 2026, Syngen Biotech Co., Ltd. generated 2.10B in revenue and converted that into 228.56M in net income, yielding earnings per share of 8.42. EBITDA reached 397.63M, while operating income came in at 280.13M.

As of June 30, 2026, Syngen Biotech Co., Ltd. holds 204.80M in cash and equivalents against 273.63M in total debt, resulting in a net debt position of -92.87M. Total book value stands at 2.34B, with working capital of 603.16M providing operational flexibility.

Syngen Biotech Co., Ltd. produced 111.02M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -86.01M in capital expenditures, free cash flow totaled 25.01M - equivalent to 0.92 per share.

Over the twelve months ended June 30, 2026, Syngen Biotech Co., Ltd. posted a gross margin of 32.38, reflecting its pricing power and cost economics. The operating margin of 13.36 and net profit margin of 10.90 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Syngen Biotech Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.04, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Syngen Biotech Co., Ltd. shareholders.

Syngen Biotech Co., Ltd.'s most recent stock split took place on September 19, 2019 with a 787:803 split ratio.

As of June 30, 2026, Syngen Biotech Co., Ltd. has an Altman Z-Score of 3.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.